In Vitro Diagnostics Market to 2018 - Consolidation, Decentralization and Demand for Genetic Testing to Shape the Competitive Landscape by GBIResearch

VIEWS: 45 PAGES: 135

More Info
									       In Vitro Diagnostics Market to 2018 - Consolidation,
    Decentralization and Demand for Genetic Testing to Shape
                    the Competitive Landscape
 Reference Code: GBIME0067MR                                                                                           Publication Date: March 2012


                                    In Vitro Diagnostics Market Forecast to Increase at a CAGR of 6.8% during 2011–2018
The global In Vitro                   In Vitro Diagnostics Market, Global, Revenue ($bn), 2011–2018
Diagnostics (IVD) market
is forecast to grow at a                                   80
Compounded Annual
Growth Rate (CAGR) of
6.8% during 2011-2018 to                                   70
reach a value of $72.3
billion by 2018
                                                           60                      CAGR 6.8%



                                                           50
                                           Revenue ($bn)




                                                           40



                                                           30



                                                           20



                                                           10



                                                            0
                                                                         2011                                               2018


                                      Source: GBI Research, Company Annual Reports, Interviews with Industry Expert and Key Opinion Leaders, Investor
                                      Presentations, News and Press Releases




                                    The global In Vitro Diagnostics (IVD) market is forecast to grow at a Compounded Annual Growth
                                    Rate (CAGR) of 6.8% during 2011-2018 to reach a value of $72.3 billion by 2018. The IVD market
                                    will be driven by the shift to preventive healthcare from curative healthcare, the increase in the
                                    incidence of infectious diseases, the increase in the percentage of elderly people and technological
                                    advances.
                                    Technological advances such as automation, biosensor technology, miniaturization, integration of
                                    workstations, and Information Technology (IT) optimizing laboratory workflow will lead to an
                                    increased demand for innovative technologies and drive the growth of the overall IVD market.
                                    Emerging countries have huge potential for IVD and demand will be high in these countries.
                                    Factors such as an increase in income levels, growing awareness among patients, an increase in
                                    the patient pool and the increased adoption of Point of Care (POC) testing will drive the market
                                    growth in these countries. The advantages of POC testing include reduced Turnaround Time
                                    (TAT), minimal infrastructure requirements and accessibility. These advantages will be major
                                    factors contributing to the increased demand for POC tests and will drive the growth of the overall
                                    IVD market.




In Vitro Diagnostics Market to 2018 - Consolidation,                                                            GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                    Page 1
Competitive Landscape                                                        © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                             reproduced, shared or resold in any form
                                    The Immunochemistry Category is expected to be the Largest Revenue Generator
                                    The immunochemistry market is expected to grow at a CAGR of 6.8% during 2011-2018. It will be
                                    the largest revenue generator in the IVD market with an expected value of $25.5 billion by 2018.
                                    Many factors, such as the increasing incidence of infectious diseases, the fast Turn Around Time
                                    (TAT) of these tests and the introduction of innovative tests, will drive the market growth.
                                    Companies are focusing on introducing new tests to meet the growing demand for
                                    immunochemistry testing across the world. The immunochemistry market has the highest number
                                    of pipeline products in the IVD market. There are a total of 1,726 pipeline products, which accounts
                                    for 59% of the total pipeline products in the IVD market.
                                    The increasing prevalence of infectious diseases and cardiac disorders and the increasing elderly
                                    population is driving the demand for immunochemistry tests. Physicians are opting for
                                    immunochemistry products over other traditional tests due to the short TAT and high specificity of
                                    the tests. This has resulted in an increased usage of immunoassays for the diagnosis of various
                                    diseases such as infectious diseases, oncology and other disorders. In order to leverage this, the
                                    companies are focusing on developing advanced immunochemistry products.
                                    Demand for Decentralized Laboratory Testing is Increasing Significantly Worldwide
                                    The healthcare delivery system has undergone a transition from hospital delivery to POC.
   The healthcare delivery          Decentralized laboratory testing is another term for near-patient testing or POC testing. It involves
   system has undergone a           clinical testing of biological samples at or near the location of patient care. Many factors have
   transition from hospital         contributed to this shift from central laboratory testing to POC testing. In POC testing the TAT is
   delivery to POC                  short as results are rapid and treatment starts without any delay, the time of sample transfer to
                                    central labs and then report generation and transfer steps are eliminated.
                                    Technological advances have also enabled POC testing to be more effective. The integration of IT
                                    with POC testing devices has improved data management and connectivity. The connectivity has
                                    enabled real time information exchange between patients and physicians leading to on time
                                    treatment. This subsequently leads to improved patient satisfaction, which drives the demand for
                                    POC testing.
                                    Accessibility is another major factor that plays a role in patients preferring POC testing. These tests
                                    need minimal infrastructural requirements and can be performed in settings such as physicians’
                                    offices, emergency rooms, intensive care units and patients’ homes.
                                    The demand for POC testing is growing significantly in emerging countries as there are a limited
                                    number of hospitals and central laboratories and the need for healthcare is constantly increasing.
                                    These factors are leading to overcrowded hospitals and long waiting times, which cause delays to
                                    treatment and patient dissatisfaction. POC testing is the preferred option to meet the growing
                                    needs of patients in countries with poor healthcare infrastructure, as POC tests can be conducted
                                    in any setting and minimize the need for proper infrastructure.
                                    All of these factors have led to the decentralization of laboratories worldwide.
                                    Genetic Testing will See a High Adoption Rate Worldwide
                                    The genetic testing market is expected to grow at a CAGR of 10.3% to reach a value of $1.9 billion
                                    by 2018. Many factors, such as direct to consumer genetic testing, growing interest in personalized
                                    medicine and an increase in the application of genetic testing in the diagnosis of infectious
                                    diseases will drive the adoption rate of genetic tests in the near future. The direct to customer
                                    genetic testing is driving the growth of the genetic testing market. The demand has increased
                                    because of improved accessibility and convenience to customers. The involvement of doctors and
                                    insurance agencies is also eliminated, which further increases the convenience for patients.
                                    The growing interest in personalized medicine is driving the genetic testing market across the
                                    world. Personalized medicine involves the practice of using genetic information to decide about
                                    medical care for an individual. Various pharmacogenomic tests are used for the prognosis and
                                    diagnosis of diseases. The increasing application of genetic testing for the diagnosis of infectious
                                    diseases is driving the overall market growth. Most laboratories are now using genetic tests for the
                                    diagnosis of infectious disease, especially for Sexually Transmitted Diseases (STDs) such as
                                    Acquired Immuno Deficiency Syndrome/ Human immunodeficiency virus (AIDS/HIV). Apart from
                                    STDs, companies are now focusing on developing a rapid test for the detection of respiratory
                                    diseases.
                                    These factors will drive the adoption rate of genetic testing worldwide.


In Vitro Diagnostics Market to 2018 - Consolidation,                                                     GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                             Page 2
Competitive Landscape                                                 © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                      reproduced, shared or resold in any form
                                    F. Hoffmann-La Roche Ltd. and Siemens Healthcare were the Leading Companies in the
                                    Global in Vitro Diagnostics Market in 2010

                                      In Vitro Diagnostics Market, Global, Company Share (%), 2010


                                                                                                   F. Hoffmann-La Roche
                                                                                                            Ltd.
                                                                                                           11%



                                                                                                                  Siemens Healthcare
                                                                                                                        11%




                                                                                                                      Abbott Laboratories
                                                                                                                             10%



                                                       Others
                                                        68%




                                      Source: GBI Research, Company Annual Reports, Interviews with Industry Expert and Key Opinion Leaders, Investor
                                      Presentations, News and Press Releases




                                    F. Hoffmann-La Roche Ltd. and Siemens Healthcare were the leading companies in the global IVD
                                    market in 2010, each with a market share of 11%. The IVD market is fragmented and large
                                    numbers of smaller companies are operating in this market. The wide product portfolio of F.
                                    Hoffmann-La Roche Ltd. helped it gain an 11% market share in the IVD market. The company has
                                    acquired mtm Laboratories, which has expanded its tissue diagnostics products portfolio. Siemens’
                                    acquisition of Bayer’s diagnostic portfolio helped it to become a key company in the IVD market
                                    with an 11% share.
                                    These two companies are closely followed by Abbott with a 10% market share. Abbott offers a
                                    broad range of innovative IVD systems and tests for hospitals, reference labs, blood banks,
                                    physicians’ offices and clinics. Abbott is a strong company in the POC testing market and has a
                                    wide product portfolio of rapid tests and POC.
                                    Emerging Countries Will be the Key Focus Areas for IVD Companies
                                    Emerging countries such as India, China and Brazil hold good potential for IVD companies. Pricing
                                    pressures in developed countries and increased healthcare spending in emerging countries are the
                                    factors why IVD companies are expanding their presence in emerging markets. Other favorable
                                    factors for IVD companies include the huge untapped market, the demand for rapid tests and POC
                                    testing, increased awareness among patients, the increase in government initiatives to provide
                                    better healthcare facilities, the increasing elderly population and the increasing incidence of various
                                    diseases. All of these factors have resulted in an increase in demand for IVD.
                                    The lack of proper infrastructure will propel the growth of POC testing in these markets. POC tests
                                    are portable, easy to use and do not require any expertise or infrastructure. The growing incidence
                                    of diseases such as diabetes, obesity, cardiac disorders and other chronic conditions are major
                                    factors driving the demand for POC testing.
                                    Government initiatives investing in the healthcare sector are also driving the IVD demand in these
                                    countries. Due to the increase in the healthcare budget, there has been an increase in the number
                                    of hospitals and primary care centers. This increase has subsequently led to an increased demand


In Vitro Diagnostics Market to 2018 - Consolidation,                                                            GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                    Page 3
Competitive Landscape                                                        © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                             reproduced, shared or resold in any form
                                    for IVD. In China, the demand for IVD is increasing due to increased government healthcare
                                    spending, the increased elderly population, the untapped market and the replacement of obsolete
                                    IVD devices. Due to the low penetration rate there is a huge untapped market in China. On
                                    average, only 50% of the hospitals in China have biochemistry analyzers. This presents a good
                                    opportunity for IVD devices in China.
                                    With an increase in demand for IVD devices, reagents will also experience a similar rise in demand
                                    as they are complementary products. In India, the increase in disposable income, the increase in
                                    the patient pool, the growing elderly population and the increasing rate of obesity are expected to
                                    drive the IVD market. Obesity and old age are the major risk factors for chronic diseases. The
                                    chronic diseases require frequent testing, which will drive the growth of the IVD market.
                                    The penetration into rural parts of India is also increasing. This includes diagnostic private chains
                                    such as SRL Ranbaxy, which have high workflow and also attract business from hospitals in the
                                    US and UK that outsource their pathology demands.
                                    The factors presented above demonstrate the favorable market opportunities for IVD companies in
                                    emerging countries. Companies such as Abbott, Roche and Siemens and smaller companies, such
                                    as BioMerieux, Transasia, Becton Dickenson, Beckman Coulter, Johnson & Johnson (J&J) and
                                    Sysmex, are expanding their presence in emerging countries such as India, China, Brazil and
                                    Russia.
                                    The US was the Largest Market for the IVD Industry in 2011
                                    The US was the largest market for IVD and accounted for 50% of the global IVD market in 2011.
   The US was the largest           The IVD market was valued at $19.4 billion in 2011 and is forecast to grow at a CAGR of 6.6% to
   market for IVD and               reach $30.3 billion by 2018. In the US, the genetic testing category is the fastest growing category
   accounted for 50% of the         and is expected to increase at a CAGR of 11.3% to reach $1.1 billion by 2018. The market is
   global IVD market in 2011        expected to be driven by the increasing adoption of genetic testing by physicians. The completion
                                    of a human genome project has also increased the application areas for genetic testing.
                                    The shift to preventive healthcare will drive the demand for IVD. Technological advances leading to
                                    short TAT, improved specificity and accuracy, automation, and the introduction of innovative POC
                                    testing will drive the market growth.




In Vitro Diagnostics Market to 2018 - Consolidation,                                                     GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                             Page 4
Competitive Landscape                                                 © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                      reproduced, shared or resold in any form
                                    1         Table of Contents
                                    1 Table of Contents ........................................................................................................................ 5
                                      1.1    List of Tables..................................................................................................................... 9
                                      1.2    List of Figures ................................................................................................................. 10
                                    2 Introduction ................................................................................................................................ 12
                                      2.1    GBI Research Guidance ................................................................................................. 12
                                    3 Global In Vitro Diagnostics Market: Market Characterization .................................................... 13
                                      3.1    Global in Vitro Diagnostics Market, Revenue ($bn), 2004–2011..................................... 13
                                      3.2    Global In Vitro Diagnostics Market, Revenue ($bn), 2011–2018 .................................... 15
                                      3.3    Global In Vitro Diagnostics Market, Key Company Shares (%), 2010............................. 17
                                      3.4    Global In Vitro Diagnostics Market: Key Market Trends .................................................. 18
                                         3.4.1    Growing Trend towards Preventive Healthcare is Driving the Growth of In Vitro
                                                  Diagnostics .............................................................................................................. 18
                                         3.4.2    Increased Use of Information Technology in IVD for Effective Workflow Management
                                                   ................................................................................................................................ 19
                                         3.4.3    Laboratory Consolidation is a Major Trend in the IVD Industry ............................... 20
                                         3.4.4    Demand for Decentralized Laboratory Testing is increasing Significantly Across the
                                                  World ....................................................................................................................... 22
                                         3.4.5    Consolidation Activity has Increased Significantly in the IVD Industry in Recent
                                                  Years ....................................................................................................................... 22
                                         3.4.6    Automation is the Key Technology Trend in IVD Market ......................................... 23
                                      3.5    Global In Vitro Diagnostics Market: Market Dynamics .................................................... 25
                                         3.5.1    Market Drivers ......................................................................................................... 25
                                         3.5.2    Market Restraints .................................................................................................... 26
                                    4 Global In Vitro Diagnostics Market: Market Category Analysis and Forecasts .......................... 27
                                      4.1    In Vitro Diagnostics Market: Cross-Category Analysis .................................................... 27
                                      4.2    Immunochemistry............................................................................................................ 29
                                         4.2.1    Immunochemistry Market, Global, Revenue ($m), 2004–2011................................ 29
                                         4.2.2    Immunochemistry Market, Global, Revenue ($m), 2011–2018................................ 30
                                         4.2.3    Immunochemistry Market, Global, Company Share, (%), 2010 ............................... 31
                                      4.3    Immunochemistry Market: Market Dynamics .................................................................. 32
                                         4.3.1    Market Drivers ......................................................................................................... 32
                                         4.3.2    Market Restraints .................................................................................................... 34
                                      4.4    Clinical Chemistry ........................................................................................................... 35
                                         4.4.1    Clinical Chemistry Market, Global, Revenue ($m), 2004–2011 ............................... 35
                                         4.4.2    Clinical Chemistry Market, Global, Revenue ($m), 2011–2018 ............................... 36
                                         4.4.3    Clinical Chemistry Market, Global, Key Company Shares, (%), 2010 ..................... 37
                                      4.5    Clinical Chemistry Market: Market Dynamics .................................................................. 38
                                         4.5.1    Market Drivers ......................................................................................................... 38
                                         4.5.2    Market Restraints .................................................................................................... 40
                                      4.6    Infectious Immunology .................................................................................................... 41
                                         4.6.1    Infectious Immunology Market, Global, Revenue ($m), 2004–2011 ........................ 41
                                         4.6.2    Infectious Immunology Market, Global, Revenue ($m), 2011–2018 ........................ 42
                                         4.6.3    Infectious Immunology Market, Global, Key Company Shares, (%), 2010 .............. 43
                                      4.7    Infectious Immunology Market: Market Dynamics........................................................... 44
                                         4.7.1    Market Drivers ......................................................................................................... 44
                                         4.7.2    Market Restraints .................................................................................................... 45
                                      4.8    Hematology ..................................................................................................................... 46
                                         4.8.1    Hematology Market, Global, Revenue ($m), 2004–2011......................................... 46
                                         4.8.2    Hematology Market, Global, Revenue ($m), 2011–2018......................................... 47
                                         4.8.3    Hematology Market, Global, Key Company Shares, (%), 2010 ............................... 48
                                      4.9    Hematology Market: Market Dynamics ........................................................................... 49
                                         4.9.1    Market Drivers ......................................................................................................... 49
                                         4.9.2    Market Restraints .................................................................................................... 49
                                      4.10 Microbiology Culture ....................................................................................................... 50

In Vitro Diagnostics Market to 2018 - Consolidation,                                                                    GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                            Page 5
Competitive Landscape                                                                © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                         4.10.1 Microbiology Culture Market, Global, Revenue ($m), 2004–2011 ........................... 50
                                         4.10.2 Microbiology Culture Market, Global, Revenue ($m), 2011–2018 ........................... 51
                                         4.10.3 Microbiology Culture Market, Global, Company Shares, (%), 2010......................... 52
                                      4.11 Microbiology Culture Market: Market Dynamics .............................................................. 53
                                         4.11.1 Market Drivers ......................................................................................................... 53
                                         4.11.2 Market Restraints .................................................................................................... 53
                                      4.12 Histology and Cytology ................................................................................................... 54
                                         4.12.1 Histology and Cytology Market, Global, Revenue ($m), 2004–2011 ....................... 54
                                         4.12.2 Histology and Cytology Market, Global, Revenue ($m), 2011–2018 ....................... 55
                                         4.12.3 Histology and Cytology Market, Global, Company Share, (%), 2010 ...................... 56
                                      4.13 Histology and Cytology Market: Market Dynamics .......................................................... 57
                                         4.13.1 Market Drivers ......................................................................................................... 57
                                         4.13.2 Market Restraints .................................................................................................... 57
                                      4.14 Genetic Testing ............................................................................................................... 58
                                         4.14.1 Genetic Testing Market, Global, Revenue ($m), 2004–2011................................... 58
                                         4.14.2 Genetic Testing Market, Global, Revenue ($m), 2011–2018................................... 59
                                         4.14.3 Genetic Testing Market, Global, Company Share, (%), 2010 .................................. 60
                                      4.15 Genetic Testing Market: Market Dynamics ..................................................................... 61
                                         4.15.1 Market Drivers ......................................................................................................... 61
                                         4.15.2 Market Restraints .................................................................................................... 62
                                    5 Global In Vitro Diagnostics Market: Country Analysis and Forecasts ........................................ 63
                                      5.1    In Vitro Diagnostics Market: Cross-Country Analysis ...................................................... 63
                                      5.2    Historic and Forecast Revenue, By Country ................................................................... 65
                                         5.2.1    In Vitro Diagnostics Market, The US, Revenue ($m), 2004–2011 ........................... 65
                                         5.2.2    In Vitro Diagnostics Market, the US, Revenue ($m), 2011–2018 ............................ 66
                                         5.2.3    In Vitro Diagnostics Market, Canada, Revenue ($m), 2004–2011. .......................... 67
                                         5.2.4    In Vitro Diagnostics Market, Canada, Revenue ($m), 2011–2018 ........................... 68
                                         5.2.5    In Vitro Diagnostics Market, the UK, Revenue ($m), 2004–2011 ............................ 69
                                         5.2.6    In Vitro Diagnostics Market, the UK, Revenue ($m), 2011–2018 ............................ 70
                                         5.2.7    In Vitro Diagnostics Market, Germany, Revenue ($m), 2004–2011......................... 71
                                         5.2.8    In Vitro Diagnostics Market, Germany, Revenue ($m), 2011–2018......................... 72
                                         5.2.9    In Vitro Diagnostics Market, France, Revenue ($m), 2004–2011 ............................ 73
                                         5.2.10 In Vitro Diagnostics Market, France, Revenue ($m), 2011–2018 ............................ 74
                                         5.2.11 In Vitro Diagnostics Market, Italy, Revenue ($m), 2004–2011 ................................. 75
                                         5.2.12 In Vitro Diagnostics Market, Italy, Revenue ($m), 2011–2018 ................................. 76
                                         5.2.13 In Vitro Diagnostics Market, Spain, Revenue ($m), 2004–2011 .............................. 77
                                         5.2.14 In Vitro Diagnostics Market, Spain, Revenue ($m), 2011–2018 .............................. 78
                                         5.2.15 In Vitro Diagnostics Market, Japan, Revenue ($m), 2004–2011.............................. 79
                                         5.2.16 In Vitro Diagnostics Market, Japan, Revenue ($m), 2011–2018.............................. 80
                                         5.2.17 In Vitro Diagnostics Market, China, Revenue ($m), 2004–2011 .............................. 81
                                         5.2.18 In Vitro Diagnostics Market, China, Revenue ($m), 2011–2018 .............................. 82
                                         5.2.19 In Vitro Diagnostics Market, India, Revenue ($m), 2004–2011................................ 83
                                         5.2.20 In Vitro Diagnostics Market, India, Revenue ($m), 2011–2018................................ 84
                                         5.2.21 In Vitro Diagnostics Market, Australia, Revenue ($m), 2004–2011 ......................... 85
                                         5.2.22 In Vitro Diagnostics Market, Australia, Revenue ($m), 2011–2018 ......................... 86
                                         5.2.23 In Vitro Diagnostics Market, Brazil, Revenue ($m), 2004–2011 .............................. 87
                                         5.2.24 In Vitro Diagnostics Market, Brazil, Revenue ($m), 2011–2018 .............................. 88
                                    6 Global In Vitro Diagnostics Market: Competitive Assessment ................................................... 89
                                      6.1    Key Market Participants .................................................................................................. 90
                                         6.1.1    F. Hoffmann–La Roche Ltd...................................................................................... 90
                                         6.1.2    Siemens Healthcare (Subsidiary of Siemens AG) ................................................... 91
                                         6.1.3    Abbott Laboratories ................................................................................................. 92
                                         6.1.4    Beckman Coulter, Inc. (Subsidiary of Danaher Corporation) ................................... 93
                                         6.1.5    Ortho–Clinical Diagnostics Inc. (Subsidiary of Johnson & Johnson) ....................... 94
                                         6.1.6    bioMerieux S.A. (Subsidiary of Merieux Alliance group) .......................................... 94

In Vitro Diagnostics Market to 2018 - Consolidation,                                                                 GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                         Page 6
Competitive Landscape                                                             © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                  reproduced, shared or resold in any form
                                         6.1.7    Sysmex Corporation (Sysmex) ................................................................................ 95
                                         6.1.8    Becton, Dickinson and Company............................................................................. 96
                                         6.1.9    Bio–Rad Laboratories, Inc. (Bio–Rad) ..................................................................... 97
                                         6.1.10 Alere Inc. (formerly Inverness Medical Innovations, Inc.) ........................................ 98
                                    7 Global In Vitro Diagnostics Market: Product Pipeline Analysis .................................................. 99
                                      7.1    In Vitro Diagnostics Market: Pipeline Products Summary ............................................... 99
                                         7.1.1    Pipeline Products Analysis: Immunochemistry Market .......................................... 101
                                         7.1.2    Pipeline Products Analysis: Infectious Immunology............................................... 102
                                         7.1.3    Pipeline Products Analysis: Genetic Testing ......................................................... 103
                                         7.1.4    Pipeline Products Analysis: Clinical Chemistry ...................................................... 104
                                         7.1.5    Pipeline Products Analysis: Hematology ............................................................... 105
                                         7.1.6    Pipeline Products Analysis: Microbiology Culture .................................................. 106
                                         7.1.7    Pipeline Products Analysis: Histology and Cytology .............................................. 107
                                      7.2    In Vitro Diagnostics Market: Profiles of Key Pipeline Products ..................................... 108
                                         7.2.1    ImmProCon Technology ........................................................................................ 108
                                         7.2.2    RAPIDPoint 500 System – Lactate Assay ............................................................. 108
                                         7.2.3    Sali – Chek Reader ............................................................................................... 108
                                         7.2.4    Point-of-Care Diagnostic Device............................................................................ 109
                                         7.2.5    ACE Alera Clinical Chemistry System – Direct A1c Assay .................................... 109
                                         7.2.6    Advia 120 Hematology System – IRF Test ............................................................ 109
                                         7.2.7    Advia 2120 Hematology System – MPC Test ........................................................ 110
                                         7.2.8    AIA–600 II – D–dimer Test .................................................................................... 110
                                    8 Global In Vitro Diagnostics Market: Consolidation Landscape ................................................ 111
                                      8.1    Deals by Number, 2008–2011 ...................................................................................... 111
                                      8.2    In Vitro Diagnostics Market: Key Deals, 2008–2011 ..................................................... 119
                                         8.2.1    Roche Completes Acquisition of mtm laboratories ................................................ 119
                                         8.2.2    bioMerieux Acquires Argene.................................................................................. 119
                                         8.2.3    Thermo Fisher Completes Acquisition of Phadia ................................................... 119
                                         8.2.4    Quest Diagnostics Completes Acquisition of Athena Diagnostics ......................... 120
                                         8.2.5    Danaher Completes Acquisition of Beckman Coulter ............................................ 120
                                         8.2.6    Laboratory Corporation of America Completes Acquisition of Genzyme Genetics
                                                  From Genzyme ...................................................................................................... 121
                                         8.2.7    Merck Completes Acquisition of Millipore .............................................................. 121
                                         8.2.8    Thermo Fisher Scientific Completes Acquisition of Ahura Scientific ...................... 121
                                         8.2.9    Inverness Medical Innovations Acquires 78.13% Stake in Standard Diagnostics.. 122
                                         8.2.10 Quidel Completes Acquisition of Diagnostic HYBRIDS ......................................... 122
                                         8.2.11 Danaher Completes Acquisition of Genetix Group ................................................ 122
                                         8.2.12 QIAGEN Completes Acquisition of DxS ................................................................ 122
                                         8.2.13 Thermo Fisher Scientific Completes Acquisition of B.R.A.H.M.S. ......................... 123
                                         8.2.14 Laboratory Corporation of America Holdings Completes Acquisition of Monogram
                                                  Biosciences ........................................................................................................... 123
                                         8.2.15 Inverness Medical Innovations Completes Acquisition of Concateno From Marwyn
                                                    124
                                         8.2.16 Gen–Probe Acquires Tepnel Life Sciences ........................................................... 124
                                         8.2.17 Hologic Acquires Third Wave Technologies .......................................................... 124
                                         8.2.18 Immucor Acquires BioArray Solutions ................................................................... 124
                                         8.2.19 Werfen Life Acquires INOVA Diagnostics.............................................................. 125
                                         8.2.20 Abbott Laboratories Acquires Ibis Biosciences from Isis Pharmaceuticals ............ 125
                                         8.2.21 bioMerieux Acquires AviaraDx............................................................................... 125
                                         8.2.22 Bio–Rad Laboratories Acquires Diamed................................................................ 126
                                    9 Appendix ................................................................................................................................. 127
                                      9.1    Definitions ..................................................................................................................... 127
                                         9.1.1    Clinical Chemistry .................................................................................................. 127
                                         9.1.2    Immunochemistry Test Reagents .......................................................................... 128
                                         9.1.3    Hematology ........................................................................................................... 129


In Vitro Diagnostics Market to 2018 - Consolidation,                                                                   GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                           Page 7
Competitive Landscape                                                               © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                    reproduced, shared or resold in any form
                                          9.1.4    Histology And Cytology ......................................................................................... 130
                                          9.1.5    Microbiology Culture .............................................................................................. 131
                                          9.1.6    Infectious Immunology ........................................................................................... 131
                                          9.1.7    Genetic Testing ..................................................................................................... 132
                                       9.2    Sources ......................................................................................................................... 132
                                       9.3    Acronyms ...................................................................................................................... 132
                                       9.4    Research Methodology ................................................................................................. 133
                                          9.4.1    Secondary Research ............................................................................................. 133
                                          9.4.2    Primary Research .................................................................................................. 134
                                          9.4.3    Models ................................................................................................................... 134
                                          9.4.4    Forecasts ............................................................................................................... 134
                                          9.4.5    Expert Panels ........................................................................................................ 134
                                       9.5    Contact Us .................................................................................................................... 135
                                       9.6    Disclaimer ..................................................................................................................... 135




In Vitro Diagnostics Market to 2018 - Consolidation,                                                                  GBIME0067MR / Published MAR 2012
Decentralization and Demand for Genetic Testing to Shape the                                                                                          Page 8
Competitive Landscape                                                              © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                   reproduced, shared or resold in any form
                                    1.1     List of Tables
                                    Table 1:    In Vitro Diagnostics Market, Global, Revenue ($bn), 2004–2011................................... 13
                                    Table 2:    In Vitro Diagnostics Market, Global, Revenue ($bn), 2011–2018................................... 15
                                    Table 3:    Global In Vitro Diagnostics Market, Key Company, Revenue ($m) 2010 ....................... 17
                                    Table 4:    In Vitro Diagnostics Market, Global, Diagnostics Laboratories, Key M&A Deals, 2007 .. 20
                                    Table 5:    In Vitro Diagnostics Market, Global, Diagnostics Laboratories, Key M&A Deals, 2008–
                                                2009 ............................................................................................................................... 21
                                    Table 6:    Key M&A, IVD Market, Global, 2010–2011 .................................................................... 23
                                    Table 7:    In Vitro Diagnostics Market, Global, Cross Category Analysis ,CAGR (%), 2004–2018 27
                                    Table 8:    Immunochemistry Market, Global, Revenue ($m), 2004–2011 ...................................... 29
                                    Table 9:    Immunochemistry Market, Global, Revenue ($m), 2011–2018 ...................................... 30
                                    Table 10:   Global Immunochemistry Market, Key Company, Revenue ($m) 2010.......................... 31
                                    Table 11:   Global Immunochemistry Market, Tumor Markers ......................................................... 33
                                    Table 12:   Clinical Chemistry Market, Global, Revenue ($m), 2004–2011 ...................................... 35
                                    Table 13:   Clinical Chemistry Market, Global, Revenue ($m), 2011–2018 ...................................... 36
                                    Table 14:   Clinical Chemistry Market, Global, Key Company Revenue ($m), 2010 ........................ 37
                                    Table 15:   Infectious Immunology Market, Global, Revenue ($m), 2004–2011............................... 41
                                    Table 16:   Infectious Immunology Market, Global, Revenue ($m), 2011–2018............................... 42
                                    Table 17:   Infectious Immunology Market, Global, Key Company, Revenue ($m) 2010 ................. 43
                                    Table 18:   Hematology Market, Global, Revenue ($m), 2004–2011 ............................................... 46
                                    Table 19:   Hematology Market, Global, Revenue ($m), 2011–2018 ............................................... 47
                                    Table 20:   Hematology Market, Global, Key Company Revenue ($m), 2010 .................................. 48
                                    Table 21:   Microbiology Culture Market, Global, Revenue ($m), 2004–2011 .................................. 50
                                    Table 22:   Microbiology Culture Market, Global, Revenue ($m), 2011–2018 .................................. 52
                                    Table 23:   Microbiology Culture Market, Global, Key Company Revenue ($m), 2010 .................... 53
                                    Table 24:   Histology and Cytology Market, Global, Revenue ($m), 2004–2011 .............................. 54
                                    Table 25:   Histology and Cytology Market, Global, Revenue ($m), 2011–2018 .............................. 55
                                    Table 26:   Histology and Cytology Market, Global, Key Company, Revenue ($m) 2010 ................ 56
                                    Table 27:   Genetic Testing Market, Global, Revenue ($m), 2004–2011 ......................................... 58
                                    Table 28:   Genetic Testing Market, Global, Revenue ($m), 2011–2018 ......................................... 59
                                    Table 29:   Genetic Testing Market, Global, Key Company Revenue ($m), 2010 ............................ 60
                                    Table 30:   In Vitro Diagnostics Market, Global, Genetic Testing, Home Genetic Test Kits, Examples
                                                ....................................................................................................................................... 61
                                    Table 31:   IVD Market, Global, Cross-Country Analysis, CAGR (%), 2004–2018 ........................... 63
                                    Table 32:   In Vitro Diagnostics Market, The US, Revenue ($m), 2004–2011 .................................. 65
                                    Table 33:   In Vitro Diagnostics Market, The US, Revenue ($m), 2011–2018 .................................. 66
                                    Table 34:   In Vitro Diagnostics Market, Canada, Revenue ($m), 2004–2011 ................................. 67
                                    Table 35:   In Vitro Diagnostics Market, Canada, Revenue ($m), 2011–2018 ................................. 68
                                    Table 36:   In Vitro Diagnostics Market, The UK, Revenue ($m), 2004–2011 .................................. 69
                                    Table 37:   In Vitro Diagnostics Market, The UK, Revenue ($m), 2011–2018 .................................. 70
                                    Table 38:   In Vitro Diagnostics Market, Germany, Revenue ($m), 2004–2011 ............................... 71
                                    Table 39:   In Vitro Diagnostics Market, the Germany, Revenue ($m), 2011–2018 ......................... 72
                                    Table 40:    In Vitro Diagnostics Market, France, Revenue ($m), 2004–2011.................................. 73
                                    Table 41:   In Vitro Diagnostics Market, France, Revenue ($m), 2011–2018 ................................... 74
                                    Table 42:   In Vitro Diagnostics Market, Italy, Revenue ($m), 2004–2011 ....................................... 75
                                    Table 43:   In Vitro Diagnostics Market, Italy, Revenue ($m), 2011–2018 ....................................... 76
                                    Table 44:   In Vitro Diagnostics Market, Spain, Revenue ($m), 2004–2011 ..................................... 77
                                    Table 45:   In Vitro Diagnostics Market, Spain, Revenue ($m), 2011–2018 ..................................... 78
                                    Table 46:   In Vitro Diagnostics Market, Japan, Revenue ($m), 2004–2011 .................................... 79
                                    Table 47:   In Vitro Diagnostics Market, Japan, Revenue ($m), 2011–2018 .................................... 80
                                    Table 48:   In Vitro Diagnostics Market, China, Revenue ($m), 2004–2011..................................... 81
                                    Table 49:   In Vitro Diagnostics Market, China, Revenue ($m), 2011–2018..................................... 82
                                    Table 50:   In Vitro Diagnostics Market, India, Revenue ($m), 2004–2011 ...................................... 83
                                    Table 51:   In Vitro Diagnostics Market, India, Revenue ($m), 2011–2018 ...................................... 84
                                    Table 52:   In Vitro Diagnostics Market, Australia, Revenue ($m), 2004–2011 ................................ 85
                                    Table 53:   In Vitro Diagnostics Market, Australia, Revenue ($m), 2011–2018 .....................
								
To top